Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

Cerenome secures Florida Blue deal, expanding CNSide’s coverage to 164 million lives.

What the company is saying

Cerenome, through CNSide Diagnostics, is announcing a new in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026. The company frames this as a milestone, emphasizing that it is the first CNSide agreement to cover both tumor cell enumeration and molecular profiling tests for CNS cancers. The release highlights the addition of approximately 6 million covered lives, bringing CNSide’s total in-network coverage to about 164 million commercial and Medicare Advantage lives. Marc Hedrick, M.D., President and CEO, positions this as a key step in broadening CNSide’s diagnostics platform and commercial reach. The announcement stresses clinical validation, referencing a peer-reviewed study of 1,391 CSF specimens and 12 supporting publications, as well as over 11,000 tests performed since 2020 at more than 120 U.S. cancer institutions. The tone is confident, focusing on scale, clinical adoption, and the expansion of reimbursed test offerings.

What the data suggests

The agreement with Florida Blue is effective immediately as of October 1, 2026, and adds approximately 6 million covered lives to CNSide’s payer footprint. CNSide now claims in-network agreements representing about 164 million covered lives across commercial and Medicare Advantage segments. Since 2020, more than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions, indicating some degree of clinical uptake. The company’s molecular profiling approach was evaluated in a real-world study of 1,391 CSF specimens, and the tumor cell analysis is supported by 12 peer-reviewed publications and multicenter study evidence. The announcement does not provide reimbursement rates, revenue figures, or financial impact, so the direct economic benefit of the expanded coverage cannot be assessed. The data supports operational growth and clinical validation, but leaves the financial trajectory and actual market penetration within the covered population unquantified.

Analysis

The announcement is generally positive and well-supported by operational data, including the execution of a new payer agreement with Florida Blue, the expansion to 164 million covered lives, and evidence of clinical adoption (over 11,000 tests performed at more than 120 institutions). The majority of key claims are realised and supported by specific numbers or peer-reviewed studies. However, the tone is somewhat inflated by highlighting the scale of coverage and clinical reach without disclosing any financial metrics such as revenue, profit, or reimbursement rates, making it impossible to assess the financial impact or sustainability of this growth. Some forward-looking statements (e.g., upcoming product launches, clinical trials, and AI platform ambitions) are present but do not dominate the narrative. The absence of capital outlay or long-dated benefit claims keeps the hype moderate rather than high.

Risk flags

• ●The absence of disclosed reimbursement rates or financial terms means the revenue impact of the Florida Blue agreement is unknown; this limits visibility into profitability and return on expanded coverage.
• ●While CNSide’s in-network agreements now represent 164 million covered lives, actual test adoption within this population is not quantified, creating uncertainty about true market penetration and demand.
• ●The company relies on clinical validation and peer-reviewed evidence, but does not provide comparative performance data or outcomes versus standard-of-care diagnostics, which may affect payer and physician uptake.
• ●Future growth depends on continued execution of the national reimbursement strategy and successful adoption by clinicians, both of which are subject to competitive and operational risks.

Bottom line

Cerenome’s new agreement with Florida Blue adds 6 million covered lives, expanding CNSide’s in-network footprint to approximately 164 million, and marks the first time both tumor cell enumeration and molecular profiling tests are covered under a single payer contract. The announcement is backed by operational data—over 11,000 tests performed since 2020, use at more than 120 institutions, and validation in a 1,391-specimen study—but does not disclose any financial metrics or reimbursement rates. While the scale of coverage is impressive, the lack of revenue or margin data means investors cannot assess the financial impact or sustainability of this growth. The agreement’s benefits are near-term, but realization of value will depend on actual test uptake and physician adoption within the expanded population. The most important takeaway is that Cerenome is executing on its commercial strategy and broadening access, but the financial upside remains unquantified until more detailed metrics are disclosed.

Announcement summary

(NASDAQ:CNSY) Cerenome, Inc., through its wholly-owned subsidiary CNSide Diagnostics, LLC, announced it has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026. The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test and CNSide® CSF Molecular Profile tests for both solid tumors and hematologic malignancies involving the central nervous system. This is the first CNSide payer agreement to include both tumor cell enumeration and molecular profiling. The Florida Blue agreement adds approximately 6 million covered lives to CNSide’s contracted payer footprint. With this addition, CNSide now has in-network agreements representing approximately 164 million commercial and Medicare Advantage covered lives. The agreement expands CNSide’s contracted reimbursement beyond tumor cell detection in leptomeningeal metastases to include molecular profiling of CNS malignancies. CNSide® CSF Molecular Profile - Solid Tumor provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed primary CNS tumors or solid tumors metastatic to the CNS, including brain and leptomeningeal metastases. CNSide® CSF Molecular Profile - Hematologic Malignancy provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed hematologic malignancies involving the CNS. CNSide® CSF Molecular Profile tests are now commercially available through CNSide. The DNA and RNA CSF molecular profiling approach was recently evaluated in a peer-reviewed, real-world study of 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS, published in The Journal of Liquid Biopsy. The clinical utility of CNSide CSF tumor cell analysis in leptomeningeal metastases is supported by evaluation in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. Since 2020, more than 11,000 CNSide® tests have been performed at more than 120 U.S. cancer institutions. CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes CSF-based diagnostic tests for cancers involving the central nervous system. CNSide currently offers CNSide® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and plans to launch CNSide® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS in October 2026. Cerenome’s lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The company’s data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Disagree with this article?